In Vivo Anti-Inflammatory Effect of H1 Antihistamines in Allergic Rhinitis: A Randomized Clinical Trial

Balkan Med J. 2015 Oct; 32(4): 352–358.

Published online 2015 Oct 1. doi:  10.5152/balkanmedj.2015.15884

PMCID: PMC4692333

Corina I. Bocşan,¹ Adriana I. Bujor,² Nicolae Miron,² Ştefan C. Vesa,¹ Diana Deleanu,² and Anca D. Buzoianu²

Abstract

Background:

Allergic rhinitis is characterized by a chronic inflammation of nasal mucosa and represents a risk factor for asthma occurrence. H1 antihistamines reduce the symptoms of rhinitis, but some compounds may have anti-inflammatory properties.

Aims:

We evaluated the plasma level of some cytokines in patients with persistent allergic rhinitis (PAR) and their evolution after a 4-week treatment with H1 anti-histamines, as well as the risk of asthma after 1.5 years.

Intakes of apple juice, fruit drinks and soda are associated with prevalent asthma in US children aged 2–9 years

Volume 19 / Issue 01 / January 2016, pp 123-130

Luanne Robalo DeChristopher^a1 c1 p1, Jaime Uribarri^a2 and Katherine L Tucker^a3

Abstract

Objective High soft drink consumption has been linked with asthma. Anecdotal evidence links high-fructose corn syrup with asthma. The receptor of advanced glycation end products (RAGE) has emerged as a mediator of asthma. The objectives of the present study were to: (i) assess the correlation between intake of beverages containing excess free fructose (EFF beverages) and asthma in children; and (ii) epidemiologically test the mechanistic hypothesis that intake of high EFF beverages, such as apple juice or beverages sweetened with high-fructose corn syrup, is associated with increased risk of asthma. This hypothesis is based on the possible effect of increases in thein situ intestinal formation of advanced glycation end products (enFruAGE) with EFF, which may be absorbed and play a role in RAGE-mediated asthma.

Serum allergen-specific IgE testing: How much is too much?

The Choosing Wisely campaign and others advocate against indiscriminate IgE testing in evaluating allergy

CCJM 2016 Jan;83(1):21-24.

10.3949/ccjm.83a.14125

CHERYL K. LAU, PhD
Calgary Laboratory Services, Calgary, Alberta, Canada

CHRISTOPHER NAUGLER, MD, CCFP, FCFP, FRCPC*Calgary Laboratory Services, Calgary, Alberta, Canada; Division Head, General Pathology, Department of Pathology and Laboratory Medicine, Department of Family Medicine, Associate Professor, University of Calgary, Alberta, Canada

A 25-YEAR-OLD MAN is evaluated for angioedema (swelling of lips and tongue) after eating paella at a Spanish restaurant. He has no history of allergies, but he says he had never eaten such a large variety of seafood before, especially shellfish.

Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice

Journal of Asthma and Allergy - Dove Press Open Access Publisher

David Price,^1,2 Andrew M Wilson,³ Alison Chisholm,⁴ Anna Rigazio,² Anne Burden,² Michael Thomas,⁵Christine King²

¹Centre for Academic Primary Care, The Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, ²Research in Real-Life, Cambridge, ³Norwich Medical School, University of East Anglia, Norwich, ⁴Respiratory Effectiveness Group, Cambridge, ⁵Primary Medical Care, University of Southampton, Southampton, UK
Purpose: Acute, severe asthma exacerbations can be difficult to predict and thus prevent. Patients who have frequent exacerbations are of particular concern. Practical exacerbation predictors are needed for these patients in the primary-care setting.

Three-month validation of a turbuhaler electronic monitoring device: implications for asthma clinical trial use

BMJ Open Resp Res 2015;2:e000097 doi:10.1136/bmjresp-2015-000097

• Janine Pilcher1,2, 
• Philippa Shirtcliffe1,2, 
• Mitesh Patel2,3, 
• Steve McKinstry2,
• Terrianne Cripps1,2, 
• Mark Weatherall1,4 and 
• Richard Beasley1,2

Abstract

Background Electronic monitoring of inhaled asthma therapy is suggested as the ‘gold standard’ for measuring patterns of medication use in clinical trials. The SmartTurbo (Adherium (NZ) Ltd, Auckland, New Zealand) is an electronic monitor for use with a turbuhaler device (AstraZeneca, UK). The aim of this study was to determine the accuracy of the SmartTurbo in recording Symbicort actuations over a 12-week period of use.

Management of the polyallergic patient with allergy immunotherapy: a practice-based approach

Review

Pascal Demoly^12*, Giovanni Passalacqua³, Oliver Pfaar⁴⁵, Joaquin Sastre⁶ and Ulrich Wahn⁷

Allergy, Asthma & Clinical Immunology 2016, 12:2  doi:10.1186/s13223-015-0109-6

Abstract

The great majority (60–80 %) of patients consulting specialist physicians for allergic respiratory disease are polysensitized and thus may be potentially clinically polyallergic. However, management approaches to allergen immunotherapy (AIT) in polysensitized and polyallergic patients are not standardized.

An international group of clinicians with in-depth expertise in AIT product development, clinical trials and clinical practice met to generate up-to-date, unambiguous, pragmatic guidance on AIT in polysensitized and polyallergic patients. The guidance was developed after reviewing (1) the current stance of regulatory bodies and learned societies, (2) the literature data on single- and multi-AIT and (3) the members’ confirmed clinical experience with polysensitized patients.

Allergen Challenge Chamber: an innovative solution in allergic rhinitis diagnosis

Postep Derm Alergol 2015; XXXII (6): 421–425

DOI (digital object identifier): 10.5114/pdia.2015.56096

 

Edyta Krzych-Fałta, Jerzy Sowa, Oksana Wojas, Barbara Piekarska, Adam Sybilski, Bolesław Samoliński

The Allergen Challenge Chamber (ACC) is definitely a serious challenge on the one hand and an innovative solution in allergic rhinitis diagnosis on the other.

Effects of oral vitamin E on treatment of atopic dermatitis: A randomized controlled trial

J Res Med Sci 2015;20:1053-7

Fariba Jaffary, Gita Faghihi, Arghavan Mokhtarian, Sayed Mohsen Hosseini

ABSTRACT

Background: The pathogenesis of atopic dermatitis (AD) remains to be determined; recently a possible change in the immune system with production of immunoglobulins is proposed. As vitamin E is a potent antioxidant, with the ability to decrease the serum levels of immunoglobulin E (IgE) in atopic patients, we aimed to evaluate the effect of oral vitamin E on treatment of AD.